J&J Suspends Enrollment In Golimumab Trials Due To Distribution Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
Suspension is not expected to disrupt filing timeline for the rheumatoid arthritis drug, which is being developed with Schering-Plough.
You may also be interested in...
J&J/Centocor Files Golimumab In Three Indications
Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
J&J/Centocor Files Golimumab In Three Indications
Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
Hassan discusses Schering’s late-stage pipeline, including the protease inhibitor boceprevir for hepatitis C and SCH 530348, a thrombin receptor agonist intended as an add-on to Plavix therapy.